Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 3:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Diabetic Macular Edema, Age-related Macular Degeneration
Interventions: MTP-131; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Leber Congenital Amaurosis
Interventions: Not listed
Lead sponsor: MeiraGTx UK II Ltd; Industry
Eligibility: 3 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Parkinson Disease, Diabetes Mellitus, Type 1, Macular Degeneration, ALS, Cancer, Alzheimer Disease, Huntington Disease
Interventions: Biological sample collection; Other
Lead sponsor: New York Stem Cell Foundation Research Institute; Other
Eligibility: 1 Month to 100 Years
Enrollment: 1,279 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Sevirumab, Foscarnet sodium, Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • San Jose, California + 13 more

Conditions: LCA5
Interventions: AAV8.hLCA5; Biological
Lead sponsor: Opus Genetics, Inc; Industry
Eligibility: 4 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Dallas, Texas

Conditions: Age-related Macular Degeneration
Interventions: E10030; Drug
Lead sponsor: Ophthotech Corporation; Industry
Eligibility: 50 Years to 100 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Macular Degeneration
Interventions: Omega-3 fatty acid; Dietary Supplement
Lead sponsor: Wills Eye; Other
Eligibility: 55 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Cherry Hill, New Jersey • Bethlehem, Pennsylvania • Huntingdon Valley, Pennsylvania + 1 more

Conditions: Diabetic Retinopathy
Interventions: Vitreosolve; Drug
Lead sponsor: Vitreoretinal Technologies, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 10
States / cities: Phoenix, Arizona • Beverly Hills, California • Santa Ana, California + 7 more

Conditions: Retinoblastoma, Cancer Survivor, Biological Sibling, Intraocular Retinoblastoma, Unilateral Retinoblastoma
Interventions: Biospecimen collection, Vision assessment, Questionnaire administration, Quality of life assessment, Laboratory Biomarker Analysis; Procedure · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: Not listed
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2031
U.S. locations: 10
States / cities: Chicago, Illinois • Minneapolis, Minnesota • St Louis, Missouri + 5 more

Conditions: Macular Edema
Interventions: dexamethasone 700 ㎍ intravitreal implant; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 18
States / cities: Phoenix, Arizona • San Francisco, California • Santa Ana, California + 15 more

Conditions: Age-Related Maculopathy, Choroidal Neovascularization
Interventions: Ranibizumab, Verteporfin; Drug
Lead sponsor: Oklahoma State University Center for Health Sciences; Other
Eligibility: 50 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Laser photocoagulation; Procedure
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 32
States / cities: Palm Springs, California • Fort Lauderdale, Florida • Fort Myers, Florida + 26 more

Conditions: Diabetic Macular Edema (DME)
Interventions: 4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL); Biological
Lead sponsor: 4D Molecular Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 57
States / cities: Scottsdale, Arizona • Encino, California • Fullerton, California + 50 more

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Ovarian Cancer, Retinoblastoma, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: filgrastim, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 2
States / cities: New York, New York

Conditions: Retinitis Pigmentosa (RP), Usher Syndrome
Interventions: Placebo, NPI-001; Drug
Lead sponsor: Nacuity Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Retinal Vein Occlusion
Interventions: pegaptanib sodium; Drug
Lead sponsor: Eyetech Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 35
States / cities: Tucson, Arizona • Los Angeles, California • Santa Ana, California + 30 more

Conditions: Age-Related Macular Degeneration
Interventions: Foresee Home; Device
Lead sponsor: Notal Vision Inc.; Industry
Eligibility: Not listed
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Toms River, New Jersey

Conditions: Geographic Atrophy, Age Related Macular Degeneration, AMD, Atrophy, Geographic
Interventions: ALK-001 oral capsule, Placebo oral capsule; Drug
Lead sponsor: Alkeus Pharmaceuticals, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 24
States / cities: Phoenix, Arizona • Beverly Hills, California • Lakewood, Colorado + 20 more

Conditions: Neovascular Age-Related Macular Degeneration (nAMD)
Interventions: 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL); Biological
Lead sponsor: 4D Molecular Therapeutics; Industry
Eligibility: 50 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 60
States / cities: Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 55 more

Conditions: Retinal Dystrophy
Interventions: nL-PRPH2-001; Drug
Lead sponsor: n-Lorem Foundation; Other
Eligibility: Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 9,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2033
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemi-retinal Vein Occlusion
Interventions: Faricimab, Port Delivery System with Ranibizumab; Drug · Combination Product
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 6,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 18
States / cities: Phoenix, Arizona • Pasadena, California • Sacramento, California + 15 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Roche Global Development; Other
Eligibility: 3 Months to 12 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 3 more

Conditions: Radiation Retinopathy
Interventions: 0.5 mg ranibizumab, Targeted Retinal Photocoagulation (TRP); Drug · Procedure
Lead sponsor: Greater Houston Retina Research; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 4
States / cities: Dallas, Texas • Houston, Texas • Katy, Texas + 1 more

Search by objective public record fields.

A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration

Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65

Biological Sample Collection for Research and Biobanking

Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS

Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients

A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration

Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degeneration

A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects

Studying Health Outcomes After Treatment in Patients With Retinoblastoma

An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)

Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration

The Course of Response to Focal Photocoagulation for DME

A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors

A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

ForeseeHome NRich Registry

Phase 2/3 Study of ALK-001 in Geographic Atrophy

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy

A Post-Authorization, Long-term Study of Ozanimod Real-world Safety

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children

Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.